The report highlights the company's progress in 2022, including the launch of three first-in-class medicines, the achievement of significant regulatory and clinical milestones, and the expansion of its research and development capabilities through acquisitions and partnerships. The report also highlights the company's commitment to health equity, inclusion and diversity, and environmental sustainability. The company has made significant progress toward its goals in these areas, including the distribution of nearly $100 million in grant funding to support programs and services that address health inequities, the achievement of gender parity in its global workforce, and the reduction of greenhouse gas emissions by 8.2%.
Issuing Company Bristol-Myers Squibb Company
Report Type Sustainability Report
Report Language EN
Report Filesize 19.1 MB
No. of Pages 107 pages
Reporting periodJanuary 1, 2022-December 31, 2022
Report EditionUnknown
Assurance Provider Apex
Reporting Standards GRI; SASB; Biopharma Investor ESG Communications Guidance 4....
Materiality Assessmenttrue